Patents by Inventor Margaret Bradbury

Margaret Bradbury has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Formulations and Pharmacokinetics of Deuterated Benzoquinoline Inhibitors of Vesicular Monoamine Transporter 2
    Publication number: 20240366591
    Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
    Type: Application
    Filed: January 2, 2024
    Publication date: November 7, 2024
    Inventors: Andreas Sommer, Chengzhi Zhang, John Carter, John Charles Arthur, Margaret Bradbury, Thomas George Gant, Manouchehr Shahbaz
  • PHARMACEUTICAL FORMULATIONS
    Publication number: 20230355514
    Abstract: The present invention relates to new extended release pharmaceutical compositions and methods of use thereof for the treatment of disorders.
    Type: Application
    Filed: February 21, 2023
    Publication date: November 9, 2023
    Inventors: Andreas SOMMER, Chengzhi ZHANG, John CARTER, John ARTHUR, Margaret BRADBURY
  • Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
    Patent number: 11666566
    Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
    Type: Grant
    Filed: April 27, 2020
    Date of Patent: June 6, 2023
    Assignee: Auspex Pharmaceuticals, Inc.
    Inventors: Andreas Sommer, Chengzhi Zhang, John Carter, John Charles Arthur, Margaret Bradbury, Thomas George Gant, Manouchehr Shahbaz
  • NOVEL PHARMACEUTICAL FORMULATIONS
    Publication number: 20210322308
    Abstract: The present invention relates to new extended release pharmaceutical compositions and methods of use thereof for the treatment of disorders.
    Type: Application
    Filed: January 12, 2021
    Publication date: October 21, 2021
    Inventors: Andreas SOMMER, Chengzhi ZHANG, John CARTER, John ARTHUR, Margaret BRADBURY
  • Formulations and Pharmacokinetics of Deuterated Benzoquinoline Inhibitors of Vesicular Monoamine Transporter 2
    Publication number: 20210244723
    Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
    Type: Application
    Filed: March 25, 2021
    Publication date: August 12, 2021
    Inventors: Andreas Sommer, Chengzhi Zhang, John Carter, John Charles Arthur, Margaret Bradbury, Thomas George Gant, Manouchehr Shahbaz
  • NOVEL PHARMACEUTICAL FORMULATIONS
    Publication number: 20210205214
    Abstract: The present invention relates to new extended release pharmaceutical compositions and methods of use thereof for the treatment of disorders.
    Type: Application
    Filed: March 3, 2021
    Publication date: July 8, 2021
    Inventors: Andreas SOMMER, Chengzhi ZHANG, John CARTER, John ARTHUR, Margaret BRADBURY
  • Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
    Patent number: 11033540
    Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
    Type: Grant
    Filed: November 13, 2019
    Date of Patent: June 15, 2021
    Assignee: Auspex Pharmaceuticals, Inc.
    Inventors: Andreas Sommer, Chengzhi Zhang, John Carter, John Charles Arthur, Margaret Bradbury, Thomas George Gant, Manouchehr Shahbaz
  • Pharmaceutical formulations
    Patent number: 10966922
    Abstract: The present invention relates to new extended release pharmaceutical compositions and methods of use thereof for the treatment of disorders.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: April 6, 2021
    Assignee: Auspex Pharmaceuticals, Inc.
    Inventors: Andreas Sommer, Chengzhi Zhang, John Carter, John Arthur, Margaret Bradbury
  • Formulations and Pharmacokinetics of Deuterated Benzoquinoline Inhibitors of Vesicular Monoamine Transporter 2
    Publication number: 20200289498
    Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
    Type: Application
    Filed: November 13, 2019
    Publication date: September 17, 2020
    Inventors: Andreas Sommer, Chengzhi Zhang, John Carter, John Charles Arthur, Margaret Bradbury, Thomas George Gant, Manouchehr Shahbaz
  • Formulations and Pharmacokinetics of Deuterated Benzoquinoline Inhibitors of Vesicular Monoamine Transporter 2
    Publication number: 20200253952
    Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
    Type: Application
    Filed: April 27, 2020
    Publication date: August 13, 2020
    Inventors: Andreas Sommer, Chengzhi Zhang, John Carter, John Charles Arthur, Margaret Bradbury, Thomas George Gant, Manouchehr Shahbaz
  • NOVEL PHARMACEUTICAL FORMULATIONS
    Publication number: 20190328661
    Abstract: The present invention relates to new extended release pharmaceutical compositions and methods of use thereof for the treatment of disorders.
    Type: Application
    Filed: July 12, 2019
    Publication date: October 31, 2019
    Inventors: Andreas SOMMER, Chengzhi ZHANG, John CARTER, John ARTHUR, Margaret BRADBURY
  • NOVEL PHARMACEUTICAL FORMULATIONS
    Publication number: 20190133935
    Abstract: The present invention relates to new extended release pharmaceutical compositions and methods of use thereof for the treatment of disorders.
    Type: Application
    Filed: November 1, 2018
    Publication date: May 9, 2019
    Inventors: Andreas SOMMER, Chengzhi ZHANG, John CARTER, John ARTHUR, Margaret BRADBURY
  • Formulations And Pharmacokinetics Of Deuterated Benzoquinoline Inhibitors Of Vesicular Monoamine Transporter 2
    Publication number: 20190083484
    Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
    Type: Application
    Filed: October 17, 2018
    Publication date: March 21, 2019
    Inventors: Andreas Sommer, Chengzhi Zhang, John Carter, John Arthur, Margaret Bradbury, Thomas Gant, Manouchehr Shahbaz
  • Pharmaceutical formulations
    Patent number: 10166183
    Abstract: The present invention relates to new extended release pharmaceutical compositions and methods of use thereof for the treatment of disorders. In certain embodiments, disclosed herein is an extended-release pharmaceutical formulation comprising, in a solid dosage form for oral delivery of between about 100 mg and about 1 g total weight: between about 2 and about 18% of an active ingredient; between about 70% and about 96% of one or more diluents; between about 1% and about 10% of a water-soluble binder and between about 0.5 and about 2% of a surfactant.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: January 1, 2019
    Assignee: Auspex Pharmaceuticals, Inc.
    Inventors: Andreas Sommer, Chengzhi Zhang, John Carter, John Arthur, Margaret Bradbury
  • Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
    Patent number: 9814708
    Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
    Type: Grant
    Filed: February 16, 2016
    Date of Patent: November 14, 2017
    Assignee: Auspex Pharmaceuticals, Inc.
    Inventors: Andreas Sommer, Chengzhi Zhang, John Carter, John Arthur, Margaret Bradbury, Thomas Gant, Manouchehr Shahbaz
  • FORMULATIONS PHARMACOKINETICS OF DEUTERATED BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2
    Publication number: 20170087147
    Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
    Type: Application
    Filed: October 6, 2016
    Publication date: March 30, 2017
    Inventors: Andreas Sommer, Chengzhi Zhang, John Carter, John Arthur, Margaret Bradbury, Thomas Gant, Manouchehr Shahbaz
  • Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
    Patent number: 9550780
    Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: January 24, 2017
    Assignee: Auspex Pharmaceuticals, Inc.
    Inventors: Andreas Sommer, Chengzhi Zhang, John Carter, John Arthur, Margaret Bradbury, Thomas Gant, Manouchehr Shahbaz
  • NOVEL PHARMACEUTICAL FORMULATIONS
    Publication number: 20160346200
    Abstract: The present invention relates to new extended release pharmaceutical compositions and methods of use thereof for the treatment of disorders. In certain embodiments, disclosed herein is an extended-release pharmaceutical formulation comprising, in a solid dosage form for oral delivery of between about 100 mg and about 1 g total weight: between about 2 and about 18% of an active ingredient; between about 70% and about 96% of one or more diluents; between about 1% and about 10% of a water-soluble binder and between about 0.5 and about 2% of a surfactant.
    Type: Application
    Filed: February 5, 2015
    Publication date: December 1, 2016
    Inventors: Andreas SOMMER, Chengzhi ZHANG, John CARTER, John ARTHUR, Margaret BRADBURY
  • FORMULATIONS and PHARMACOKINETICS OF DEUTERATED BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2
    Publication number: 20160235733
    Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
    Type: Application
    Filed: February 16, 2016
    Publication date: August 18, 2016
    Inventors: Andreas Sommer, Chengzhi Zhang, John Carter, John Arthur, Margaret Bradbury, Thomas Gant, Manouchehr Shahbaz
  • FORMULATIONS PHARMACOKINETICS OF DEUTERATED BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2
    Publication number: 20160222008
    Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
    Type: Application
    Filed: March 16, 2016
    Publication date: August 4, 2016
    Inventors: Andreas Sommer, Chengzhi Zhang, John Carter, John Arthur, Margaret Bradbury, Thomas Gant, Manouchehr Shahbaz